RECURSION PHARMACEUTICALS, INC. Finite-Lived License Agreements, Gross
RECURSION PHARMACEUTICALS, INC. (RXRX) had Finite-Lived License Agreements, Gross of $9.00 million as of 2024-06-30, per its 10-Q filed 2024-08-08.
Discontinued › Balance Sheet › Assets › Intangible Asset, Finite-Lived, after Accumulated Amortization › Intangible Asset, Finite-Lived, before Accumulated Amortization
us-gaap:FiniteLivedLicenseAgreementsGross · last filed 2024-08-08
- 2024-06-30: Finite-Lived License Agreements, Gross $9.00M.
| Period end | Finite-Lived License Agreements, Gross |
|---|---|
| 2024-06-30 | $9.00M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |